DiaMedica Therapeutics Net Income
| DMAC Stock | USD 7.90 0.50 5.95% |
As of the 4th of February, DiaMedica Therapeutics shows the Semi Deviation of 4.48, downside deviation of 4.78, and Mean Deviation of 3.47. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
DiaMedica Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DiaMedica Therapeutics' valuation are provided below:DiaMedica Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. DiaMedica | Build AI portfolio with DiaMedica Stock |
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
DiaMedica Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DiaMedica Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DiaMedica Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in DiaMedica Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding DiaMedica Therapeutics or generate 0.0% return on investment in DiaMedica Therapeutics over 90 days. DiaMedica Therapeutics is related to or competes with Altimmune, Galectin Therapeutics, EnGene Holdings, Annexon, Alpha Tau, Frequency Therapeutics, and Design Therapeutics. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney... More
DiaMedica Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DiaMedica Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DiaMedica Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.78 | |||
| Information Ratio | 0.0925 | |||
| Maximum Drawdown | 24.12 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 7.69 |
DiaMedica Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for DiaMedica Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DiaMedica Therapeutics' standard deviation. In reality, there are many statistical measures that can use DiaMedica Therapeutics historical prices to predict the future DiaMedica Therapeutics' volatility.| Risk Adjusted Performance | 0.0864 | |||
| Jensen Alpha | 0.3869 | |||
| Total Risk Alpha | 0.1421 | |||
| Sortino Ratio | 0.0922 | |||
| Treynor Ratio | 0.249 |
DiaMedica Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0864 | |||
| Market Risk Adjusted Performance | 0.259 | |||
| Mean Deviation | 3.47 | |||
| Semi Deviation | 4.48 | |||
| Downside Deviation | 4.78 | |||
| Coefficient Of Variation | 943.2 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.71 | |||
| Information Ratio | 0.0925 | |||
| Jensen Alpha | 0.3869 | |||
| Total Risk Alpha | 0.1421 | |||
| Sortino Ratio | 0.0922 | |||
| Treynor Ratio | 0.249 | |||
| Maximum Drawdown | 24.12 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 7.69 | |||
| Downside Variance | 22.86 | |||
| Semi Variance | 20.06 | |||
| Expected Short fall | (3.80) | |||
| Skewness | (0.29) | |||
| Kurtosis | 1.23 |
DiaMedica Therapeutics Backtested Returns
DiaMedica Therapeutics appears to be slightly risky, given 3 months investment horizon. DiaMedica Therapeutics secures Sharpe Ratio (or Efficiency) of 0.11, which denotes the company had a 0.11 % return per unit of standard deviation over the last 3 months. By reviewing DiaMedica Therapeutics' technical indicators, you can evaluate if the expected return of 0.51% is justified by implied risk. Please utilize DiaMedica Therapeutics' Semi Deviation of 4.48, mean deviation of 3.47, and Downside Deviation of 4.78 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, DiaMedica Therapeutics holds a performance score of 8. The firm shows a Beta (market volatility) of 1.99, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DiaMedica Therapeutics will likely underperform. Please check DiaMedica Therapeutics' mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether DiaMedica Therapeutics' price patterns will revert.
Auto-correlation | 0.10 |
Insignificant predictability
DiaMedica Therapeutics has insignificant predictability. Overlapping area represents the amount of predictability between DiaMedica Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DiaMedica Therapeutics price movement. The serial correlation of 0.1 indicates that less than 10.0% of current DiaMedica Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | -0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, DiaMedica Therapeutics reported net income of (24.44 Million). This is 107.16% lower than that of the Biotechnology sector and 134.9% lower than that of the Health Care industry. The net income for all United States stocks is 104.28% higher than that of the company.
DiaMedica Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DiaMedica Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DiaMedica Therapeutics could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics of similar companies.DiaMedica Therapeutics is currently under evaluation in net income category among its peers.
DiaMedica Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 370.94 M | ||||
| Shares Outstanding | 52.08 M | ||||
| Shares Owned By Insiders | 26.30 % | ||||
| Shares Owned By Institutions | 45.47 % | ||||
| Number Of Shares Shorted | 4.23 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 8.25 X | ||||
| EBITDA | (26.64 M) | ||||
| Net Income | (24.44 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Short Ratio | 13.50 X | ||||
| Earnings Per Share | (0.71) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 15.5 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 437.45 M | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Working Capital | 39.22 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
| Net Asset | 46.34 M |
About DiaMedica Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.